8-K: Karyopharm Reports Q1 2025 Financial Results, Highlights Myelofibrosis Data

Karyopharm Therapeutics announced its Q1 2025 financial results, including a 5% increase in XPOVIO demand, and shared new data suggesting selinexor's potential in treating myelofibrosis.

Summary

• Karyopharm Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• XPOVIO demand increased by 5% compared to Q1 2024.
• Total revenue was $30.0 million, while U.S. XPOVIO net product revenue was $21.1 million, impacted by a $5.0 million increase in product return reserve.
• The company reaffirmed its full-year 2025 total revenue guidance of $140 million to $155 million, including U.S. XPOVIO net product revenue guidance of $115 million to $130 million.
• The Phase 3 SENTRY trial in myelofibrosis passed its futility analysis and is approximately 80% enrolled, with target enrollment expected in June/July 2025.
• The company is exploring alternatives to extend its cash runway.
• The company reported a net loss of $23.5 million, or $2.77 per basic and diluted share, for the first quarter of 2025.
• Cash, cash equivalents, restricted cash and investments as of March 31, 2025 totaled $70.3 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's positive news regarding XPOVIO demand and clinical trial progress, concerns about revenue decline and cash runway extension efforts temper the overall outlook.

Positives

• XPOVIO demand increased by 5% in the first quarter of 2025 compared to the first quarter of 2024.
• Royalty revenue increased 57% to $1.7 million in the first quarter of 2025 compared to the first quarter of 2024.
• The Phase 3 SENTRY trial continues as planned without any modifications following a pre-specified futility analysis.
• The company reaffirms its full-year 2025 total revenue guidance of $140 million to $155 million.
• Net loss decreased from $37.4 million in Q1 2024 to $23.5 million in Q1 2025.

Negatives

• U.S. net product revenue was $21.1 million in the first quarter of 2025 compared to $26.0 million in the first quarter of 2024.
• Net product revenue in the first quarter of 2025 was impacted by a $5.0 million increase in the product return reserve.
• Cash, cash equivalents, restricted cash and investments decreased from $109.1 million as of December 31, 2024 to $70.3 million as of March 31, 2025.
• Interest expense increased from $5.9 million for the first quarter of 2024 to $11.0 million for the first quarter of 2025.

Risks

• The company's cash is expected to fund operations into early first quarter of 2026, excluding certain debt repayments and liquidity covenants, and into early fourth quarter of 2025, taking those into account.
• The company is exploring various alternatives to extend its cash runway, which may not result in the consummation of any transaction.
• The decrease in net product revenue was due to an increase in the gross-to-net provision, primarily related to atypical product returns recorded in the first quarter of 2025, resulting in a $5.0 million increase in the product return reserve.
• The company faces competition in the multiple myeloma marketplace.

Future Outlook

Karyopharm expects total revenue for 2025 to be in the range of $140 million to $155 million, with U.S. XPOVIO net product revenue in the range of $115 million to $130 million. R&D and SG&A expenses are expected to be in the range of $240 million to $255 million. The company anticipates its current cash, cash equivalents and investments, along with revenue from XPOVIO and license agreements, will fund planned operations into early first quarter of 2026, excluding certain debt repayments and liquidity covenants.

Management Comments

• Our conviction in this trial is further strengthened by our new data in hard-to-treat myelofibrosis patients where we observed spleen volume reduction, symptom improvement, hemoglobin stabilization and evidence of disease modification with selinexor monotherapy, addressing all four hallmarks of the disease, said Richard Paulson, President and Chief Executive Officer of Karyopharm.
• The outcomes that we have observed from our multiple pre-clinical and clinical trials continue to suggest that selinexor may be additive, if not synergistic, when combined with ruxolitinib in JAKi-nave myelofibrosis patients.

Industry Context

Karyopharm is focused on developing novel cancer therapies, particularly in areas of high unmet need such as myelofibrosis, multiple myeloma, and endometrial cancer. The company's lead product, XPOVIO, is a first-in-class XPO1 inhibitor. The myelofibrosis market is competitive, with companies like Incyte (Jakafi/Ruxolitinib) already having established treatments. Karyopharm is trying to position Selinexor as a potential combination therapy with Ruxolitinib.

Comparison to Industry Standards

• Incyte's Jakafi (ruxolitinib) is a standard treatment for myelofibrosis, generating significant revenue.
• Karyopharm is aiming to demonstrate that selinexor, in combination with ruxolitinib, can offer improved outcomes compared to ruxolitinib alone.
• The spleen volume reduction rates observed in the XPORT-MF-035 trial (SVR25 of 67% and SVR35 of 33%) are promising and warrant further investigation in the Phase 3 SENTRY trial.
• Companies like Bristol Myers Squibb and Johnson & Johnson also have treatments for multiple myeloma, a key market for Karyopharm's XPOVIO.

Stakeholder Impact

• Shareholders: The financial results and clinical trial updates will impact shareholder value.
• Employees: The company's financial stability and clinical progress affect employee morale and job security.
• Patients: The development of new cancer therapies has a direct impact on patient outcomes.
• Partners: Continued collaboration with partners like Menarini and Antengene is crucial for global expansion.

Next Steps

• Announce completion of target enrollment of the Phase 3 SENTRY trial in June/July 2025.
• Report preliminary data on a subset of participants in the 60 mg cohort from the Phase 2 SENTRY-2 trial in 1H 2025.
• Report top-line results from the Phase 3 SENTRY trial in late 2025/early 2026.
• Continue to enroll patients into the Phase 3 XPORT-EC-042 trial.
• Continue to follow patients that are enrolled in the Phase 3 XPORT-MM-031 (EMN29) trial.

Key Dates

Keywords

Karyopharm, XPOVIO, Selinexor, Myelofibrosis, Multiple Myeloma, Endometrial Cancer, Financial Results, Q1 2025, SENTRY Trial, Revenue, Pharmaceutical